CARTELA R & D AB has a total of 18 patent applications. Its first patent ever was published in 2000. It filed its patents most often in EPO (European Patent Office), Australia and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are APOTECH RES & DEV LTD, EPITOMICS INC and ANNEXON INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | Australia | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | United States | 3 | |
#5 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Machines | |
#5 | Agriculture |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Animal care | |
#7 | Unspecified technologies | |
#8 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Lundgren-Akerlund Evy | 7 |
#2 | Lundgren-Aakerlund Evy | 7 |
#3 | Gullberg Donald | 5 |
#4 | Kjellman Christian | 2 |
#5 | Tsao Ming | 1 |
#6 | Bosserhoff Anja | 1 |
Publication | Filing date | Title |
---|---|---|
EP2101818A1 | Binding agents to the integrin alpha-11 subunit, and uses thereof | |
WO2008072000A2 | Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover | |
AU2007240253A1 | Marker for stem cells and its use | |
WO2008068481A1 | New compounds, methods and uses | |
WO2007107774A2 | Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer | |
EP1924595A2 | Novel peptides and uses thereof | |
US2006127398A1 | Monoclonal antibody capable of binding integrin alpha 10 beta 1 | |
AU2003239030A1 | Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation | |
AU2003222556A1 | Knockout mice and their use |